SYT9

Summary

SYT9 (synaptotagmin 9, HGNC:19265) is a protein-coding gene on chromosome 11p15.4, encoding Synaptotagmin-9 (Q86SS6). May be involved in Ca(2+)-dependent exocytosis of secretory vesicles through Ca(2+) and phospholipid binding to the C2 domain or may serve as Ca(2+) sensors in the process of vesicular trafficking and exocytosis.

Predicted to enable SNARE binding activity; calcium ion sensor activity; and calcium-dependent phospholipid binding activity. Predicted to be involved in chemical synaptic transmission; regulation of vesicle-mediated transport; and vesicle-mediated transport. Predicted to be located in clathrin-coated endocytic vesicle membrane. Predicted to be active in hippocampal mossy fiber to CA3 synapse; plasma membrane; and secretory vesicle.

Source: NCBI Gene 143425 — RefSeq curated summary.

At a glance

• GWAS associations: 12
• Clinical variants (ClinVar): 58 total
• MANE Select transcript: NM_175733

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19265
Approved symbol	SYT9
Name	synaptotagmin 9
Location	11p15.4
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000170743
Ensembl biotype	protein_coding
OMIM	613528
Entrez	143425

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 nonsense_mediated_decay, 1 protein_coding

ENST00000318881, ENST00000524820, ENST00000532592

RefSeq mRNA: 1 — MANE Select: NM_175733 NM_175733

CCDS: CCDS7778

Canonical transcript exons

ENST00000318881 — 7 exons

Exon	Start	End
ENSE00001126689	7313395	7313941
ENSE00001291376	7251904	7252331
ENSE00002166108	7466792	7469043
ENSE00003486407	7303039	7303390
ENSE00003538722	7416042	7416162
ENSE00003554085	7420506	7420635
ENSE00003626807	7417957	7418128

Expression profiles

Bgee: expression breadth ubiquitous, 153 present calls, max score 91.15.

FANTOM5 (CAGE): breadth broad, TPM avg 1.2631 / max 92.0230, expressed in 262 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
112888	0.6337	205
112887	0.4017	158
112890	0.1176	59
112889	0.1101	67

Top tissues by expression

225 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
medial globus pallidus	UBERON:0002477	91.15	gold quality
globus pallidus	UBERON:0001875	89.10	gold quality
cerebellar vermis	UBERON:0004720	83.25	silver quality
corpus callosum	UBERON:0002336	82.93	gold quality
lateral nuclear group of thalamus	UBERON:0002736	82.92	silver quality
subthalamic nucleus	UBERON:0001906	81.58	silver quality
vena cava	UBERON:0004087	81.34	gold quality
cerebellum	UBERON:0002037	81.26	gold quality
dorsal plus ventral thalamus	UBERON:0001897	81.25	gold quality
cerebellar cortex	UBERON:0002129	81.04	gold quality
cerebellar hemisphere	UBERON:0002245	80.85	gold quality
inferior vagus X ganglion	UBERON:0005363	80.48	silver quality
lateral globus pallidus	UBERON:0002476	80.45	silver quality
cardia of stomach	UBERON:0001162	80.43	gold quality
pylorus	UBERON:0001166	80.43	silver quality
ventral tegmental area	UBERON:0002691	79.98	silver quality
body of tongue	UBERON:0011876	79.96	gold quality
substantia nigra pars reticulata	UBERON:0001966	79.70	silver quality
substantia nigra pars compacta	UBERON:0001965	79.55	silver quality
superior surface of tongue	UBERON:0007371	79.51	gold quality
tongue	UBERON:0001723	79.47	gold quality
right hemisphere of cerebellum	UBERON:0014890	79.44	gold quality
medulla oblongata	UBERON:0001896	79.40	silver quality
pericardium	UBERON:0002407	79.34	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.13	gold quality
pons	UBERON:0000988	79.11	silver quality
spinal cord	UBERON:0002240	78.83	gold quality
pharyngeal mucosa	UBERON:0000355	78.82	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	78.82	gold quality
midbrain	UBERON:0001891	78.81	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.72

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

146 targeting SYT9, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-5682	99.89	72.56	1005
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-659-3P	99.85	70.69	1620
HSA-MIR-6079	99.84	68.54	1170
HSA-MIR-544A	99.84	68.66	1965
HSA-MIR-3180-5P	99.82	69.12	2422

Literature-anchored findings (GeneRIF, showing 3)

• SYT9 expression is significantly downregulated in human masticatory mucosa during wound healing (PMID:28005267)
• The intronic SYT9 variant rs11041321, which exhibits a significant genome-wide association with circulating homocysteine, was associated with the occurrence of congenital cardiac septal defects (CCSDs). This finding helps to characterize the unexpected role of SYT9 in homocysteine metabolism and the development of CCSDs, which further highlighted the interplay of diet, genetics, and human birth defects (PMID:28834160)
• The Zika virus infection remodels the expression of the synaptotagmin-9 secretory protein. (PMID:37677740)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	syt9a	ENSDARG00000003994
danio_rerio	syt9b	ENSDARG00000029239
mus_musculus	Syt9	ENSMUSG00000062542
rattus_norvegicus	Syt9	ENSRNOG00000019613

Paralogs (31): SYT7 (ENSG00000011347), SYT13 (ENSG00000019505), SYT1 (ENSG00000067715), RPH3A (ENSG00000089169), SYTL4 (ENSG00000102362), SYT17 (ENSG00000103528), SYT10 (ENSG00000110975), SYT5 (ENSG00000129990), SYT11 (ENSG00000132718), SYT4 (ENSG00000132872), SYT6 (ENSG00000134207), SYTL2 (ENSG00000137501), SYT16 (ENSG00000139973), SYTL1 (ENSG00000142765), SYT14 (ENSG00000143469), SYT2 (ENSG00000143858), SYTL5 (ENSG00000147041), SYT8 (ENSG00000149043), DOC2A (ENSG00000149927), SYTL3 (ENSG00000164674), TC2N (ENSG00000165929), SYT12 (ENSG00000173227), RPH3AL (ENSG00000181031), C2CD4C (ENSG00000183186), C2CD4A (ENSG00000198535), SYT15 (ENSG00000204176), C2CD4B (ENSG00000205502), SYT3 (ENSG00000213023), C2CD4D (ENSG00000225556), DOC2B (ENSG00000272636), SYT15B (ENSG00000277758)

Protein

Protein identifiers

Synaptotagmin-9 — Q86SS6 (reviewed: Q86SS6)

Alternative names: Synaptotagmin IX

All UniProt accessions (3): Q86SS6, B3KNT7, E9PDN4

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in Ca(2+)-dependent exocytosis of secretory vesicles through Ca(2+) and phospholipid binding to the C2 domain or may serve as Ca(2+) sensors in the process of vesicular trafficking and exocytosis.

Subunit / interactions. Homodimer; disulfide-linked via the cysteine motif. Can also form heterodimers with SYT3, SYT6, SYT7 and SYT10.

Subcellular location. Cytoplasmic vesicle. Secretory vesicle. Synaptic vesicle membrane.

Cofactor. Binds 3 Ca(2+) ions per subunit. The ions are bound to the C2 domains.

Domain organisation. The cysteine motif mediates homo- or heterodimer formation via formation of disulfide bonds.

Similarity. Belongs to the synaptotagmin family.

RefSeq proteins (1): NP_783860* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000008	C2_dom	Domain
IPR001565	Synaptotagmin	Domain
IPR035892	C2_domain_sf	Homologous_superfamily

Pfam: PF00168

UniProt features (28 total): binding site 16, sequence variant 4, topological domain 2, domain 2, chain 1, transmembrane region 1, modified residue 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86SS6-F1	75.27	0.48

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (16): 309; 309; 310; 311; 311; 311; 314; 317; 317; 383; 389; 443 …

Post-translational modifications (1): 177

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-6794361	Neurexins and neuroligins
R-HSA-8856825	Cargo recognition for clathrin-mediated endocytosis
R-HSA-8856828	Clathrin-mediated endocytosis
R-HSA-112316	Neuronal System
R-HSA-199991	Membrane Trafficking
R-HSA-5653656	Vesicle-mediated transport
R-HSA-6794362	Protein-protein interactions at synapses

MSigDB gene sets: 165 (showing top): GOBP_REGULATION_OF_VESICLE_FUSION, ACTACCT_MIR196A_MIR196B, NKX25_02, GOCC_SECRETORY_GRANULE, GOBP_VESICLE_ORGANIZATION, GOBP_MEMBRANE_FUSION, GOBP_REGULATION_OF_EXOCYTOSIS, GOBP_NEUROTRANSMITTER_TRANSPORT, RACCACAR_AML_Q6, GOBP_VESICLE_MEDIATED_TRANSPORT, REACTOME_MEMBRANE_TRAFFICKING, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, SP1_Q2_01, GOBP_CELL_CELL_SIGNALING, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT

GO Biological Process (5): chemical synaptic transmission (GO:0007268), vesicle-mediated transport (GO:0016192), regulation of calcium ion-dependent exocytosis (GO:0017158), positive regulation of vesicle fusion (GO:0031340), calcium-dependent activation of synaptic vesicle fusion (GO:0099502)

GO Molecular Function (8): SNARE binding (GO:0000149), phosphatidylserine binding (GO:0001786), calcium-dependent phospholipid binding (GO:0005544), phosphatidylinositol-4,5-bisphosphate binding (GO:0005546), identical protein binding (GO:0042802), metal ion binding (GO:0046872), calcium ion sensor activity (GO:0061891), protein binding (GO:0005515)

GO Cellular Component (9): plasma membrane (GO:0005886), clathrin-coated endocytic vesicle membrane (GO:0030669), synaptic vesicle membrane (GO:0030672), dense core granule (GO:0031045), exocytic vesicle (GO:0070382), hippocampal mossy fiber to CA3 synapse (GO:0098686), membrane (GO:0016020), cytoplasmic vesicle (GO:0031410), synapse (GO:0045202)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Protein-protein interactions at synapses	1
Clathrin-mediated endocytosis	1
Membrane Trafficking	1
Vesicle-mediated transport	1
Neuronal System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein binding	2
phospholipid binding	2
anterograde trans-synaptic signaling	1
transport	1
cellular process	1
calcium-ion regulated exocytosis	1
regulation of regulated secretory pathway	1
vesicle fusion	1
positive regulation of organelle organization	1
regulation of vesicle fusion	1
positive regulation of transport	1
synaptic vesicle exocytosis	1
positive regulation of synaptic vesicle fusion to presynaptic active zone membrane	1
anion binding	1
modified amino acid binding	1
phosphatidylinositol phosphate binding	1
phosphatidylinositol bisphosphate binding	1
cation binding	1
calcium ion binding	1
metal ion sensor activity	1
binding	1
membrane	1
cell periphery	1
clathrin-coated vesicle membrane	1
endocytic vesicle membrane	1
clathrin-coated endocytic vesicle	1
synaptic vesicle	1
exocytic vesicle membrane	1
secretory granule	1
transport vesicle	1
secretory vesicle	1
thorny excrescence	1
neuron to neuron synapse	1
hippocampal mossy fiber expansion	1
cellular anatomical structure	1
cytoplasm	1
intracellular vesicle	1
cell junction	1

Protein interactions and networks

STRING

762 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SYT9	TUBB2A	Q13885	711
SYT9	TRPV1	Q8NER1	690
SYT9	TUBB	P05218	670
SYT9	ZNF614	Q8N883	540
SYT9	VAMP8	Q9BV40	509
SYT9	STON2	Q8WXE9	462
SYT9	VAMP3	Q15836	450
SYT9	STX1A	Q16623	427
SYT9	SNAPIN	O95295	425
SYT9	SLC18A2	Q05940	421
SYT9	DLGAP3	O95886	412
SYT9	VAMP2	P19065	412
SYT9	NLGN4X	Q8N0W4	385
SYT9	SLC18A3	Q16572	384
SYT9	ZNF793	Q6ZN11	375

IntAct

12 interactions, top by confidence:

A	B	Type	Score
SLC39A5	FAM171A2	psi-mi:“MI:0914”(association)	0.640
TMBIM6	SYT9	psi-mi:“MI:0915”(physical association)	0.560
TMEM50A	SYT9	psi-mi:“MI:0915”(physical association)	0.560
UPK1B	SYT9	psi-mi:“MI:0915”(physical association)	0.560
SYT9	LRP6	psi-mi:“MI:0914”(association)	0.350
UPK1B	SYT9	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (26): SYT9 (Two-hybrid), SYT9 (Affinity Capture-MS), SYT9 (Reconstituted Complex), SYT9 (Affinity Capture-Western), TUBB (Reconstituted Complex), TUBB (Affinity Capture-Western), DNAJC5 (FRET), SYT9 (Two-hybrid), SYT9 (Two-hybrid), TMEM50A (Two-hybrid), SYT9 (Co-purification), SYT9 (Proximity Label-MS), SYT9 (Proximity Label-MS), SYT9 (Proximity Label-MS), SYNCRIP (Reconstituted Complex)

ESM2 similar proteins: A0A8I3NFE2, A0FGR8, A0FGR9, A2AP18, A4IJ05, O08625, O08874, O15357, O75038, P51432, P70218, P70268, Q01970, Q12851, Q3TZZ7, Q3U7R1, Q4VX76, Q5DTI8, Q5FWL4, Q5M7N9, Q5R8Q5, Q5RAG2, Q5RCK6, Q5RJH2, Q61161, Q62807, Q63433, Q6DN12, Q6XYQ8, Q7ZWU7, Q812E4, Q86SS6, Q8K394, Q8TDW5, Q920M7, Q925C0, Q92918, Q99JE6, Q99N48, Q9BSJ8

Diamond homologs: A0A075F932, A0FGR8, A4IJ05, K8FE10, O00445, O00750, O08625, O08835, O35681, O43581, P04409, P05128, P05129, P05130, P05696, P10102, P10829, P13677, P17252, P20444, P21521, P21579, P21707, P24505, P24506, P24507, P29101, P34693, P40748, P40749, P41823, P41885, P46096, P46097, P47191, P47708, P47709, P47861, P48018, P50232

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

58 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	49
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2134 predictions. Top by Δscore:

Variant	Effect	Δscore
11:7252332:G:GA	donor_loss	1.0000
11:7252332:G:GG	donor_gain	1.0000
11:7252333:T:A	donor_loss	1.0000
11:7303035:GCA:G	acceptor_loss	1.0000
11:7303036:CAGAT:C	acceptor_loss	1.0000
11:7303037:A:AG	acceptor_gain	1.0000
11:7303037:A:C	acceptor_loss	1.0000
11:7303038:G:GA	acceptor_loss	1.0000
11:7303038:G:GG	acceptor_gain	1.0000
11:7313942:G:GG	donor_gain	1.0000
11:7417945:T:TA	acceptor_gain	1.0000
11:7252330:AG:A	donor_gain	0.9900
11:7252331:GG:G	donor_gain	0.9900
11:7303038:GA:G	acceptor_gain	0.9900
11:7303038:GAT:G	acceptor_gain	0.9900
11:7303038:GATA:G	acceptor_gain	0.9900
11:7303038:GATAT:G	acceptor_gain	0.9900
11:7303228:G:GG	donor_gain	0.9900
11:7303395:G:GG	donor_gain	0.9900
11:7313392:AAG:A	acceptor_gain	0.9900
11:7313393:A:G	acceptor_gain	0.9900
11:7313902:G:GT	donor_gain	0.9900
11:7313937:CCAAT:C	donor_gain	0.9900
11:7313940:AT:A	donor_gain	0.9900
11:7313941:TGT:T	donor_loss	0.9900
11:7313943:TG:T	donor_loss	0.9900
11:7313944:G:GC	donor_loss	0.9900
11:7313945:A:AC	donor_loss	0.9900
11:7313946:G:T	donor_loss	0.9900
11:7321395:G:T	donor_gain	0.9900

AlphaMissense

3241 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:7313562:G:A	G222E	1.000
11:7313568:T:C	L224P	1.000
11:7313607:T:C	L237P	1.000
11:7313627:G:C	A244P	1.000
11:7313637:T:C	L247S	1.000
11:7313637:T:G	L247W	1.000
11:7313648:G:C	D251H	1.000
11:7313649:A:C	D251A	1.000
11:7313667:A:G	D257G	1.000
11:7313670:C:A	P258H	1.000
11:7313670:C:G	P258R	1.000
11:7313672:T:G	Y259D	1.000
11:7313676:T:A	V260D	1.000
11:7313718:C:T	T274I	1.000
11:7313724:T:A	V276D	1.000
11:7313731:A:C	R278S	1.000
11:7313731:A:T	R278S	1.000
11:7313745:C:A	P283H	1.000
11:7313750:T:C	F285L	1.000
11:7313752:T:A	F285L	1.000
11:7313752:T:G	F285L	1.000
11:7313805:T:A	L303H	1.000
11:7313805:T:C	L303P	1.000
11:7313823:A:C	D309A	1.000
11:7313823:A:T	D309V	1.000
11:7313825:T:C	F310L	1.000
11:7313827:T:A	F310L	1.000
11:7313827:T:G	F310L	1.000
11:7313829:A:C	D311A	1.000
11:7313829:A:T	D311V	1.000

dbSNP variants (sampled 300 via entrez): RS1000001245 (11:7270100 T>A,C), RS1000051028 (11:7262916 G>A,C), RS1000053869 (11:7401668 T>A), RS1000063979 (11:7237845 A>T), RS1000071053 (11:7328460 G>A), RS1000091370 (11:7445957 C>A), RS1000126131 (11:7378426 G>T), RS1000136516 (11:7269327 C>T), RS1000139862 (11:7394458 A>G), RS1000140365 (11:7415239 G>C), RS1000146497 (11:7368941 A>G), RS1000159323 (11:7247285 T>C), RS1000162638 (11:7430735 C>G,T), RS1000163569 (11:7349641 C>G), RS1000179528 (11:7263980 G>A,T)

Disease associations

OMIM: gene MIM:613528 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

12 associations (top):

Study	Trait	p-value
GCST001414_22	Phospholipid levels (plasma)	3.000000e-08
GCST002284_9	QRS duration in Tripanosoma cruzi seropositivity	2.000000e-07
GCST002285_14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	6.000000e-06
GCST002935_9	Lead levels	1.000000e-06
GCST006035_10	Breast cancer and/or colorectal cancer	2.000000e-06
GCST006086_19	Familial lung cancer	8.000000e-06
GCST006998_6	Cerebrospinal fluid p-tau levels in mild cognitive impairment	4.000000e-07
GCST007676_6	3-month functional outcome in ischaemic stroke (modified Rankin score)	4.000000e-06
GCST010600_4	Dietary fat liking	1.000000e-06
GCST010725_20	Malaria	4.000000e-69
GCST010725_33	Malaria	2.000000e-67
GCST010725_51	Malaria	1.000000e-55

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0006953	family history of lung cancer
EFO:0004760	t-tau measurement
EFO:0009603	stroke outcome severity measurement
EFO:0010816	dietary fat liking measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Aflatoxin B1	affects expression, decreases methylation	3
mercuric bromide	decreases expression, affects cotreatment	2
Benzo(a)pyrene	decreases expression, increases methylation	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Valproic Acid	increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
methylmercuric chloride	decreases expression	1
methyleugenol	decreases expression	1
propionaldehyde	increases expression	1
bisphenol A	affects cotreatment, increases methylation, decreases methylation	1
ethyl-p-hydroxybenzoate	decreases expression	1
trichostatin A	decreases expression, increases expression	1
butyraldehyde	increases expression	1
pentanal	increases expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Sunitinib	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Aldehydes	increases expression	1
Doxorubicin	decreases expression	1
Niclosamide	decreases expression	1
Tretinoin	increases expression	1
Triclosan	decreases expression	1
8-Bromo Cyclic Adenosine Monophosphate	increases expression	1
Cyclosporine	decreases expression	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.